AstraZeneca plc (LON:AZN) received a GBX 6,000 ($77.49) target price from equities research analysts at Citigroup Inc. in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price target indicates a potential upside of 24.84% from the company’s current price.

Several other equities research analysts have also issued reports on AZN. Shore Capital raised shares of AstraZeneca plc to a “hold” rating and set a GBX 4,800 ($61.99) price target on the stock in a report on Tuesday, May 16th. Berenberg Bank lifted their price target on shares of AstraZeneca plc from GBX 5,670 ($73.23) to GBX 5,850 ($75.55) and gave the company a “buy” rating in a report on Wednesday, May 17th. Jefferies Group LLC set a GBX 4,700 ($60.70) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a report on Saturday, May 20th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a report on Saturday, May 20th. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of “Hold” and an average price target of GBX 5,022.91 ($64.87).

AstraZeneca plc (LON:AZN) opened at 4752.50 on Wednesday. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company has a 50-day moving average of GBX 4,566.78 and a 200 day moving average of GBX 4,881.73. The firm’s market capitalization is GBX 60.17 billion.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc (AZN) Given a GBX 6,000 Price Target by Citigroup Inc. Analysts” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/15/astrazeneca-plc-azn-given-a-gbx-6000-price-target-by-citigroup-inc-analysts.html.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.